



## King's Research Portal

DOI:

[10.1373/clinchem.2016.264648](https://doi.org/10.1373/clinchem.2016.264648)

*Document Version*

Publisher's PDF, also known as Version of record

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Marjot, J., Kaier, T. E., Martin, E. D., Reji, S. S., Copeland, ON., Iqbal, M., Goodson, B., Hamren, S., Harding, S. E., & Marber, M. S. (2017). Quantifying the Release of Biomarkers of Myocardial Necrosis from Cardiac Myocytes and Intact Myocardium. *Clinical Chemistry*, 63(5), 990–996.  
<https://doi.org/10.1373/clinchem.2016.264648>

### **Citing this paper**

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### **General rights**

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### **Take down policy**

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

# Quantifying the Release of Biomarkers of Myocardial Necrosis from Cardiac Myocytes and Intact Myocardium

Jack Marjot,<sup>1†</sup> Thomas E. Kaier,<sup>1†</sup> Eva D. Martin,<sup>1</sup> Shiny S. Reji,<sup>2</sup> O'Neal Copeland,<sup>2</sup> Mohammed Iqbal,<sup>3</sup> Bob Goodson,<sup>4</sup> Sarah Hamren,<sup>4</sup> Sian E. Harding,<sup>2</sup> and Michael S. Marber<sup>1\*</sup>

**BACKGROUND:** Myocardial infarction is diagnosed when biomarkers of cardiac necrosis exceed the 99th centile, although guidelines advocate even lower concentrations for early rule-out. We examined how many myocytes and how much myocardium these concentrations represent. We also examined if dietary troponin can confound the rule-out algorithm.

**METHODS:** Individual rat cardiac myocytes, rat myocardium, ovine myocardium, or human myocardium were spiked into 400- $\mu$ L aliquots of human serum. Blood was drawn from a volunteer after ingestion of ovine myocardium. High-sensitivity assays were used to measure cardiac troponin T (cTnT; Roche, Elecsys), cTnI (Abbott, Architect), and cardiac myosin-binding protein C (cMyC; EMD Millipore, Erenna<sup>®</sup>).

**RESULTS:** The cMyC assay could only detect the human protein. For each rat cardiac myocyte added to 400  $\mu$ L of human serum, cTnT and cTnI increased by 19.0 ng/L (95% CI, 16.8–21.2) and 18.9 ng/L (95% CI, 14.7–23.1), respectively. Under identical conditions cTnT, cTnI, and cMyC increased by 3.9 ng/L (95% CI, 3.6–4.3), 4.3 ng/L (95% CI, 3.8–4.7), and 41.0 ng/L (95% CI, 38.0–44.0) per  $\mu$ g of human myocardium. There was no detectable change in cTnI or cTnT concentration after ingestion of sufficient ovine myocardium to increase cTnT and cTnI to approximately  $1 \times 10^8$  times their lower limits of quantification.

**CONCLUSIONS:** Based on pragmatic assumptions regarding cTn and cMyC release efficiency, circulating species, and volume of distribution, 99th centile concentrations may be exceeded by necrosis of 40 mg of myocardium.

This volume is much too small to detect by noninvasive imaging.

© 2017 American Association for Clinical Chemistry

Cardiac troponin (cTn),<sup>5</sup> released in the setting of myocardial necrosis, is engrained in the universal definition of myocardial infarction (1). This definition incorporates a diagnostic threshold concentration at the 99th centile for the general population. More recent guidelines suggest rule-in and rule-out cutoffs widely spaced around the 99th centile and utilize small changes in concentration between first and second blood draw (the  $\delta$  values) to identify acute myocardial injury (2). The guideline published by the European Society of Cardiology lists  $\delta$  values derived from observational studies (3–5) and advocates changes in the concentration of high-sensitivity cardiac troponin T (hs-cTnT; Roche)  $<3$  ng/L and hs-cTnI (Abbott)  $<2$  ng/L, to identify patients for early discharge (rule-out). The low magnitude of the absolute and  $\delta$  concentrations used to rule out myocardial infarction (MI) have stimulated debate (6–9). To our knowledge, no previous study has established how many myocytes, or how much myocardium, needs to undergo necrosis to exceed the 99th centile, rule out cutoff, or rule out  $\delta$  values. We set out to address this question by simulating myocardial injury using defined numbers of cardiac myocytes and quantities of myocardium spiked into human serum.

## Methods

### RAT CARDIOMYOCYTES

Adult rat ventricular myocytes were isolated from the hearts of male Wistar rats weighing approximately 200–250 g (B&K Universal Ltd.) by a collagenase-based

<sup>1</sup> King's College London BHF Centre, The Rayne Institute, St Thomas' Hospital, London, UK;

<sup>2</sup> National Heart and Lung Institute, Imperial College, London, UK; <sup>3</sup> Viapath, St Thomas' Hospital, London, UK; <sup>4</sup> EMD Millipore Corporation, Hayward, CA.

<sup>†</sup> Jack Marjot and Thomas E. Kaier contributed equally to the work, and both should be considered as first authors.

\* Address correspondence to this author at: The Rayne Institute, 4th Floor Lambeth Wing, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK. Fax +44-(0)20-

7188-0970; e-mail [mike.marber@kcl.ac.uk](mailto:mike.marber@kcl.ac.uk).

Received July 26, 2016; accepted January 6, 2017.

Previously published online at DOI: 10.1373/clinchem.2016.264648

© 2017 American Association for Clinical Chemistry

<sup>5</sup> Nonstandard abbreviations: cTn, cardiac troponin; hs-cTnT, high-sensitivity cardiac troponin T; MI, myocardial infarction; LoD, limit of detection; cMyC, cardiac myosin-binding protein C; cMRI, cardiac MRI.

enzymatic method as described in (10). In brief, hearts were excised from terminally anesthetized and heparinized (60 mg/kg sodium pentobarbitone and 100 U sodium heparin, intraperitoneally) rats. Excised hearts were immediately cannulated and initially perfused for 5 min with HEPES-Tyrode solution containing the following (mmol/L): 130 NaCl, 4.5 MgCl<sub>2</sub>, 0.4 NaH<sub>2</sub>PO<sub>4</sub>, 0.75 CaCl<sub>2</sub>, 4.2 HEPES, 20 taurine, 10 creatine, and 10 glucose. Hearts were then consecutively perfused with Ca<sup>2+</sup>-free HEPES-Tyrode solution containing 100 μmol/L EGTA (10 min) and HEPES-Tyrode solution containing 100 μmol/L CaCl<sub>2</sub> and 1 g/L type II collagenase (Worthington Biochemical Corp., 8 min). All solutions were gassed with 100% O<sub>2</sub> and maintained at 37 °C. Hearts were then removed from the perfusion apparatus, the ventricles were cut into small pieces, and agitated for a further 7 min at 37 °C. Isolated myocytes were separated from the undigested ventricular tissue by filtering through 200-μm nylon gauze, and the cells were allowed to settle by gravity (8 min). The supernatant was removed and replaced with HEPES-Tyrode solution containing 1% BSA and 500 μmol/L CaCl<sub>2</sub>. Myocytes were again allowed to settle, the supernatant was removed, and the cells were finally pooled and resuspended in 30 mL of HEPES-Tyrode solution containing 1 mmol/L CaCl<sub>2</sub>. The pooled isolated myocytes were pelleted by brief centrifugation at 50g and washed at room temperature with modified M199 culture medium (Invitrogen) containing 2 mmol/L Creatine, 2 mmol/L carnitine and 5 mmol/L taurine supplemented with 100 IU/mL penicillin/streptomycin. Following further centrifugation at 50g, myocytes were finally resuspended in modified M199 medium. Myocytes were then plated onto 6-well culture plates precoated with laminin and allowed to attach for 90 min in an incubator (37 °C, 5% CO<sub>2</sub>). Unattached cells were removed after preplating for 2 h and the culture medium was replaced with fresh modified M199 medium, and the cells were maintained overnight. Cultured rat cardiomyocytes were subsequently resuspended in Tyrode solution. Trypan blue staining revealed a viability of 45%. Cells were allowed to settle in Tyrode's solution. The solution was subsequently removed and replaced with 10 mL Tris (20 mmol, pH 7.5), then centrifuged at 94g for 3 min. The wash supernatant was discarded, and the cell pellet resuspended in fresh Tris solution. Cell count was calculated using an automated cell counter (Bio-Rad TC20™). The results of the automated cell counter were calibrated to manual cell counts attained by visual inspection with a hemocytometer. The 10 mL of resuspended pellet was then ultrasonicated (6 × 10-s bursts on ice, with 10-s intervals on ice). Dilutions of this solution were then spiked into 400 μL of banked human serum.

Experiments with cultured rat myocytes were repeated using 4 different human serum samples to ac-

count for donor-dependent interaction between human serum and rat protein. Experiments were repeated once for 2 of the serum donors using a different stock solution of cultured myocytes, so as to account for variation between culture preparations. Cells were spiked into serum in increments of 10 cells, ranging from 1 cell to 90 or 100 cells (limited by the availability of cells and serum). These repeat experiments resulted in a total of 62 samples for assessment of linear correlation.

#### HUMAN MYOCARDIUM

Human myocardium was obtained from an explanted failing heart under Ethical Approval from the Royal Brompton and Harefield Trust BRU Biobank, which complies with the Helsinki declaration of 1975. The tissue was transported in cardioplegia, and frozen at -80 °C. Frozen myocardium was weighed (the exact weight was recorded), and the tissue was crushed in a percussion mortar for 10 s. Buffer solution [50 mL Tris, pH 7.5, with 1 tablet protease inhibitor (complete EDTA-free, Roche)] was added to the pulverized tissue (1 mL of buffer per 100 mg of tissue). The subsequent solution was ultrasonicated on ice (6 × 10-s bursts on ice, with 10-s intervals on ice). Following ultrasonication, the solution was centrifuged at 21.130g for 30 mins at 4 °C. The supernatant was frozen in liquid nitrogen and then stored at -80 °C. Dilutions of this solution were then spiked into 400 μL of banked human serum.

Experiments using human myocardium were limited in number by availability of myocardial tissue, and were repeated using serum obtained from 3 different donors. Myocardium was spiked into serum at a concentration of 1 μg, 10 μg, and increments of 10 μg up to 100 μg. With addition of blank controls (serum + buffer), this resulted in a total of 36 samples for assessment of linear correlation.

#### DIETARY TROPONIN CONSUMPTION

Ovine left ventricular myocardium was boiled in water for 3 h and then mechanically homogenized using a glass handheld homogenizer. Buffer solution [50 mL Tris, pH 7.5 with 1 tablet protease inhibitor (complete EDTA-free, Roche)], was added to the homogenized tissue (1 mL of buffer per 100 mg of tissue). The subsequent solution was ultrasonicated on ice (6 × 10-s bursts on ice, with 10-s intervals on ice). Following ultrasonication, the solution was centrifuged at 21.130g for 30 mins at 4 °C. The supernatant was frozen in liquid nitrogen and then stored at -80 °C. Dilutions of this solution were then spiked into 400 μL of banked human serum to generate a calibration curve. A healthy human volunteer with a baseline serum troponin (T and I) below the limit of detection had a 200-g dietary load of ovine left ventricular myocardium boiled for 3 h. Serial venipuncture was

performed from an antecubital fossa vein at 15, 60, 120, 180, 240, 1320, and 1640 min after ingestion.

#### BIOMARKER MEASUREMENT

The concentrations of cTnI and cTnT were measured using contemporary high-sensitivity assays [Abbott Architect, limit of detection (LoD) 1.9 ng/L; and Roche Elecsys, LoD 5 ng/L, respectively], (11–13). Cardiac myosin-binding protein C (cMyC) was measured by EMD Millipore on the Erenna<sup>®</sup> platform using proprietary reagents as recently described (LoD of 0.4 ng/L) (14). A triplicate standard curve was run and used to interpolate the data.

For all samples, the biomarker concentration in the blank control was subtracted from the total biomarker concentration of each sample, to control for variation in troponin concentrations within the human serum or the background signal generated by buffer alone. Samples of Tris buffer added to banked human serum (serving as controls for each experiment) returned cTnT values between LoD and 6.98 ng/L, cTnI values between LoD and 5.00 ng/L, and cMyC values between 11.37 and 26.78 ng/L.

Likely compatibility of the high sensitivity troponin assays with rat cTn was assessed by basic local alignment search tool (BLAST) comparison of the amino acid sequence of rat troponin and the detection/capture epitopes for the high-sensitivity assay antibodies (see Fig. S1 in the Data Supplement that accompanies the online version of this article at <http://www.clinchem.org/content/vol63/issue5>). The amino acid sequence for these epitopes was largely conserved between the human and rat proteins. This molecular suggestion of compatibility was borne out in the strong signal detected by the assays in rat and ovine cardiac tissues.

#### STATISTICAL ANALYSIS

Linear regression analysis was used to assess correlation, and standardized residuals greater than  $\pm 3$  SDs were excluded as outliers ( $n = 1$ ). Statistical analysis was conducted using SPSS version 22 (IBM Corp.) and R version 3.3.0 (GUI 1.68, The R Foundation for Statistical Computing).

#### Results

The cMyC assay did not detect rat cMyC since the capture and detection antibodies are directed at human-specific sequences [see Fig. 3 in (15)]. There is a strong linear correlation between rat cardiomyocyte number and cTn concentration (cTnI;  $R^2 = 0.58$ ,  $P < 0.001$ ,  $n = 61$ ; cTnT;  $R^2 = 0.83$ ,  $P < 0.001$ ,  $n = 62$ ; Fig. 1). We were able to detect, in 400  $\mu$ L of serum, a cTn increase resulting from a single cardiomyocyte. The slope coefficients for both cTnI and cTnT were similar [cTnI slope = 18.9 ng.L<sup>-1</sup>/cell (95% CI, 14.7–23.1); cTnT

slope = 19 ng.L<sup>-1</sup>/cell (95% CI, 16.8–21.2) and the lines of regression did not deviate significantly from the origin [cTnI  $y$ -intercept = -44.6 ng.L<sup>-1</sup> (95% CI, -128.8 to 39.5) and cTnT  $y$ -intercept = 24.4 ng.L<sup>-1</sup> (95% CI, -18.9 to 67.7)]. One outlier was identified during linear regression with a standardized residual  $> 3$  SDs. No other outliers were identified, and in the context of strong linear correlations either side of this point, this outlier was assumed to represent a user-operated pipetting error.

In experiments using human myocardium, both the cTns and cMyC were strongly linearly correlated with mass of myocardium [cTnI  $R^2 = 0.92$ ,  $P < 0.001$ ,  $n = 36$ , slope = 4.3 ng.L<sup>-1</sup>/ $\mu$ g (95% CI, 3.8–4.7),  $y$ -intercept = 4.4 ng.L<sup>-1</sup> (95% CI, -20.1 to 28.8)], [cTnT  $R^2 = 0.93$ ,  $P < 0.001$ ,  $n = 36$ , slope = 3.9 ng.L<sup>-1</sup>/ $\mu$ g (95% CI, 3.6–4.3),  $y$ -intercept = 19.0 ng.L<sup>-1</sup> (95% CI, -1.6 to 39.5)], [cMyC  $R^2 = 0.96$ ,  $P < 0.001$ ,  $n = 36$ , slope = 41.0 ng.L<sup>-1</sup>/ $\mu$ g (95% CI, 38.0–44.0),  $y$ -intercept = 91.1 ng.L<sup>-1</sup> (95% CI, -79.3 to 261.4)] (Fig. 2).


Cooked ovine myocardium had a much greater troponin content than human myocardium, and a robust linear correlation was established between mass of myocardium and troponin release [hs-cTnI  $R^2 = 0.992$ ,  $P < 0.0001$ ,  $n = 12$ , slope = 4928 ng.L<sup>-1</sup>/ $\mu$ g (95% CI, 4616–5241)], [hs-cTnT  $R^2 = 0.998$ ,  $P < 0.0001$ ,  $n = 12$ , slope = 11512 ng.L<sup>-1</sup>/ $\mu$ g (95% CI, 11225–11798)]. Despite this extreme sensitivity, at all measured time points following an oral load of similarly processed ovine myocardium, the concentration of both cTnI and cTnT remained below the LoD for their respective assays when measured in human peripheral venous circulation (Fig. 3).

#### Discussion

This study documents the extreme sensitivity of the high-sensitivity cTn assays, which are capable of detecting release from a single cardiomyocyte in a 400- $\mu$ L blood sample. All investigated biomarkers correlate strongly with the mass of human myocardium. The observation that each microgram of human myocardium releases less cTn than a single cardiomyocyte most likely results from the heterogeneous cellular makeup of the human heart samples and the difficulty in efficiently liberating sarcomeric protein.

Despite the extreme sensitivity of cTn assays, we were unable to detect exogenous cTn in the peripheral blood stream after an oral load.

Based on our results, if we assume a circulating plasma volume and biomarker distribution of 2.75 L without clearance, the 99th centile concentrations for high-sensitivity assays for cTnT (Roche, 14 ng/L), cTnI (Abbott, 26 ng/L), and cMyC (87 ng/L) can be exceeded by necrosis of 0.025 g, 0.042 g, and 0.015 g of myocar-




dium, respectively (for calculation, see the online Data Supplement). The recent guideline by the European Society of Cardiology defines “rule-out” and  $\delta$  values for cTn, below which cardiac injury is unlikely (2). These values are close to the LoD concentrations of the high-sensitivity assays for cTnT and cTnI (5 ng/L and 1.9 ng/L, respectively). Our experiments suggest that 9 mg and 3 mg of human myocardial necrosis are required to increase cTnT and cTnI above their LoDs as measured by high-sensitivity assays, respectively. The corresponding value for cMyC (LoD 0.4 ng/L) is 0.07 mg. Our experiments simulate a scenario of complete myocardial necrosis, with subsequent rapid reperfusion and distribution of the coronary effluent into the systemic circulation. We have also ignored the circulating species of cTnI, cTnT, and cMyC. Collectively these, and other unknown factors, make it likely that diagnostic thresholds would in reality require myocardial necrosis more substantial than we have predicted.

The models of myocardial necrosis we have adopted are reductionist and convenient but differ markedly from necrosis of blood-perfused myocardium in vivo. Firstly,

the process of cardiomyocyte necrosis in vivo is more complex than tissue homogenization. The vast majority of cTnI, cTnT, and cMyC resides in the crystalline sarcomere and release from this compartment is slow. The cause for this slow and incomplete release is uncertain but is likely related to the quality of reperfusion since the temporal profile of cTnT differs markedly between alcohol septal ablation (low microvascular reflow) and cardioplegia (high microvasculature reflow) (15). In addition, myocardial cTnT can be readily released from myocardium by serum alone, without the need of specialist extraction buffers (16). Although, we didn't measure the cTnI, cTnT, or cMyC remaining in the insoluble fraction (pellet after centrifugation) following homogenization, it is likely extraction was inefficient since the concentration of cTnT we observed in human myocardium is lower than those published previously (16, 17). Secondly, the protracted release in vivo provides ample opportunity for posttranslational modifications, that will be absent in our models of rapid myocardial homogenization in calcium-free lysis buffers containing protease inhibitors. For example, cTnI, cMyC, and cTnT appear






in the circulation as peptides, as well as intact proteins (15, 18–20). In the case of cMyC, calpain-mediated cleavage is regulated by phosphorylation events within the M domain that impede the formation of an N-terminal peptide (21) that is both immunogenic (22) and negatively inotropic (23). Immunoassays may not have the same sensitivity for these modified forms of cTnI, cTnT, and cMyC as they do for the parental unmodified protein (18, 24). If the cleavage event occurs between the epitopes recognized by the capture and detection antibodies, the immunoassay will become insensitive. Conversely, other posttranslational modifications are known to enhance the sensitivity of immunoassays. For example, the sensitivity of assays for cTnI can be enhanced by oxidation leading to intramolecular disulfide formation and also when cTnI is in a binary or ternary complex with cTnC and cTnT (18). Furthermore, the abundance of circulating cTnI, cTnT, and cMyC peptides changes over time in an individual patient as well as between patients (15, 18, 20). There can also be marked differences between individual patients in the

proportions of cTnT and cTnI that appear in apo vs binary and ternary forms (18). These complexities were absent in our experiments where heart tissue was rapidly homogenized, protease inhibitors prevented protein cleavage, opportunities for oxidation were limited and there was no added calcium to maintain ternary complexes of cTnI/cTnC/cTnT (18). These details illustrate the simplistic assumptions made in our in vivo extrapolation of volumes of myocardial necrosis needed to cross diagnostic thresholds. Nonetheless, they do not invalidate the extreme analytic sensitivity of the cTnT, cTnI, and cMyC assays and the microscopic nature of the myocardial necrosis events that drive clinical decision-making.

Several publications have previously challenged the thresholds for AMI (acute MI) rule-out as well as the application of very small  $\delta$  values in clinical practice (6–8, 25). In their analysis, Chenevier-Gobeaux et al. questioned the cutoff for rule-out at the limit of detection (5 ng/L for cTnT), prompting Peter Kavsak to comment that there might “be other analytical factors at play that affected the performance of hs-cTnT” (6, 7). Hickman



**Fig. 3.** Graph demonstrating available serum biomarker concentration after an oral load of cooked ovine myocardium at the following time points: 0 min, 15 min, 1 h, 2 h, 3 h, 4 h (missing for cTnI), 22 h, 28 h; all measured values remained below the LoD for high-sensitivity assays (hs-cTnT and hs-cTnI) for the respective biomarkers (cTnT = 5 ng/L, cTnI = 1.9 ng/L; indicated by dotted lines on graph).

et al. (8) further highlighted the challenges associated with such narrow decision limits and the use of deltas when the cTn release might have plateaued—as is the case with late presentations to the emergency department and cTn release caused by events other than atherosclerotic plaque instability. Turer et al. have added to the diagnostic conundrum by describing low-level cTnT release in the context of ischemia without frank infarction (25). Although new myocardial scarring on cardiac magnetic resonance imaging (cMRI) has been correlated to cTn measured with a second-generation assay (26), this is limited by the inability of cMRI to detect infarct size smaller than a gram of myocardium. To our knowledge, no previous study has directly correlated cardiac damage at a tissue or cellular level to biomarker concentrations measured using contemporary high-sensitivity assays.

While there is a significant body of evidence to suggest that di- and tripeptides, derived from dietary protein can cross the gastrointestinal tract into the portal circulation, the absorption of larger intact polypeptides is controversial (27). Based on the closely spaced capture/detection epitopes used by the cTnI and cTnT assays, 20-mer polypeptides should generate a signal (see Appendix in the online Data Supplement). Given the excep-

tional sensitivity of the high-sensitivity troponin assays, we hypothesized that we would detect longer cTnI and cTnT polypeptides in the systemic circulation. This hypothesis was supported by the fact that both of the high-sensitivity assays for cTnT and cTnI were substantially more sensitive to cTn in cooked ovine than in human myocardium. Following a meal of 200 g of ovine myocardium, venous blood was sampled from a healthy human volunteer at hourly time intervals. Assuming that (a) the human digestive tract is able to liberate all the cTnT in ovine myocardium in a manner similar to ultrasonication, and (b) the entire quantity of liberated cTnT is able to cross into the systemic circulation, extrapolation of the calibration curve indicates that serum cTnT should be increased by 335 mg/L. The hs-cTnT assay has sensitivity to detect 5 ng/L increments in serum troponin. As such, only  $1.5 \times 10^{-6}\%$  of the dietary cTnT needed to be released from the myocardium and absorbed into systemic circulation to produce a detectable increase in serum cTnT. Nonetheless, measured cTnT remained consistently below the LoD at all time points after the dietary load. The same observation was made with cTnI. Even with the unrealistic assumption of complete liberation of troponin from the full mass of ingested myocardium, the

orders of magnitude involved suggest the gastrointestinal tract is virtually impervious to absorption of intact polypeptides of troponin.

In conclusion, we have, for the first time, correlated the 99th centile thresholds of cTn to the approximate mass of myocardium undergoing complete necrosis. Our experiments have revealed the exquisite sensitivity of the contemporary biomarker assays, with necrosis of just 40 mg of myocardium, equivalent to 0.015% of the heart, sufficient to increase serum concentrations above the 99th centile.

**Author Contributions:** All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

**Authors' Disclosures or Potential Conflicts of Interest:** Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest:

**Employment or Leadership:** M. Iqbal, Viapath pathology; S. Harding, Imperial College London.

**Consultant or Advisory Role:** S. Harding, BHF, MRC, Rosetrees, and British Government Science and Technology Committee.

**Stock Ownership:** None declared.

**Honoraria:** None declared.

**Research Funding:** The UK Department of Health through the National Institute for Health Biomedical Research Centre Award to Guy's & St Thomas' National Health Service Foundation Trust. T.E. Kaier, British Heart Foundation (TG/15/1/31518 and FS/15/13/31320); S. Harding, BHF; M. Marber, The Medical Research Council (UK; G1000737), Guy's & St Thomas' Charity (R060701, R100404), and British Heart Foundation (TG/15/1/31518 and FS/15/13/31320).

**Expert Testimony:** None declared.

**Patents:** M. Marber, patent no. US 8,546,089 B2, a patent held by King's College London for the detection of cMyC as a biomarker of myocardial injury.

**Role of Sponsor:** The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, and final approval of manuscript.

Millipore Sigma (Hayward, CA) was contracted to undertake the analyses of cMyC on a fee-for-service basis and hold no commercial interest.

## References

1. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. *J Am Coll Cardiol* 2012;60:1581-98.
2. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2016;37:267-315.
3. Reichlin T, Schindler C, Drexler B, Twerenbold R, Reiter M, Zellweger C, et al. One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. *Arch Intern Med* 2012;172:1211-8.
4. Rubini Giménez M, Twerenbold R, Jaeger C, Schindler C, Puelacher C, Wildi K, et al. One-hour rule-in and rule-out of acute myocardial infarction using high-sensitivity cardiac troponin I. *Am J Med* 2015;128:861-4.
5. Twerenbold R, Wildi K, Jaeger C, Gimenez MR, Reiter M, Reichlin T, et al. Optimal cutoff levels of more sensitive cardiac troponin assays for the early diagnosis of myocardial infarction in patients with renal dysfunction. *Circulation* 2015;131:2041-50.
6. Chenevier-Gobeaux C, Meune C, Lefevre G, Doumenc B, Sorbets E, Peschanski N, et al. A single value of high-sensitive troponin T below the limit of detection is not enough for ruling out non ST elevation myocardial infarction in the emergency department. *Clin Biochem* 2016;49:1113-7.
7. Kavsak PA, Saenger AK, Hickman PE. Reality check for cardiac troponin testing - sometimes the result is wrong. *Clin Biochem* 2016;49:1107-8.
8. Hickman PE, Lindahl B, Cullen L, Koerbin G, Tate J, Potter JM. Decision limits and the reporting of cardiac troponin: meeting the needs of both the cardiologist and the ED physician. *Crit Rev Clin Lab Sci* 2015;52:28-44.
9. Hickman PE, Koerbin G, Saenger AK, Kavsak PA. Statistical issues with the determination of the troponin 99th percentile - not just a problem for troponin? *Clin Biochem* 2016;49:1105-6.
10. De Nicola GF, Martin ED, Chaikuad A, Bassi R, Clark J, Martino L, et al. Mechanism and consequence of the autoactivation of p38 $\alpha$  mitogen-activated protein kinase promoted by TAB1. *Nat Struct Mol Biol* 2013;20:1182-90.
11. Apple FS, Sandoval Y, Jaffe AS, Ordonez-Llanos J, for the IFCC Task Force on Clinical Applications of Cardiac Bio-Markers. Cardiac troponin assays: guide to understanding analytical characteristics and their impact on clinical care. *Clin Chem* 2017;63:73-81.
12. Giannitsis E, Kurz K, Hallermayer K, Jarrausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. *Clin Chem* 2010;56:254-61.
13. Ryan JB, Southby SJ, Stuart LA, Mackay R, Florkowski CM, George PM. Comparison of cardiac TnI outliers using a contemporary and a high-sensitivity assay on the Abbott Architect platform. *Ann Clin Biochem* 2014;51:507-11.
14. Marjot J, Liebetrau C, Goodson RJ, Kaier T, Weber E, Heseltine P, et al. The development and application of a high-sensitivity immunoassay for cardiac myosin-binding protein C. *Transl Res* 2016;170:17-25; Suppl. Data 25.e1-25.e5.
15. Baker JO, Tyther R, Liebetrau C, Clark J, Howarth R, Patterson T, et al. Cardiac myosin-binding protein C: a potential early biomarker of myocardial injury. *Basic Res Cardiol* 2015;110:23.
16. Starnberg K, Jeppsson A, Lindahl B, Hammarsten O. Revision of the troponin T release mechanism from damaged human myocardium. *Clin Chem* 2014;60:1098-104.
17. Katus HA, Remppis A, Scheffold T, Diederich KW, Kuebler W. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. *Am J Cardiol* 1991;67:1360-7.
18. Wu AH, Feng YJ, Moore R, Apple FS, McPherson PH, Buechler KF, Bodor GF. Characterization of cardiac troponin subunit release into serum after acute myocardial infarction and comparison of assays for troponin T and I. *Clin Chem* 1998;44:1198-208. Authors are on behalf of American Association for Clinical Chemistry Subcommittee on cTnI Standardization.
19. Govindan S, McElligott A, Muthusamy S, Nair N, Barefield D, Martin JL, et al. Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction. *J Mol Cell Cardiol* 2012;52:154-64.
20. Cardinaels EPM, Mingels AMA, van Rooij T, Collinson PO, Prinzen FW, Dieijen-Visser MP. Time-dependent degradation pattern of cardiac troponin T following myocardial infarction. *Clin Chem* 2013;59:1083-90.
21. Sadayappan S, Osinska H, Kleivitsky R, Lorenz JN, Sargent M, Molkenin JD, et al. Cardiac myosin binding protein-C phosphorylation is cardioprotective. *Proc Natl Acad Sci USA* 2006;103:16918-23.
22. Lipps C, Nguyen JH, Pyttel L, Lynch TL, Liebetrau C, Aleshcheva G, et al. N-terminal fragment of cardiac myosin binding protein-C triggers pro-inflammatory responses in vitro. *J Mol Cell Cardiol* 2016;99:47-56.
23. Razzaque MA, Gupta M, Osinska H, Gulick J, Blaxall BC, Robbins J. An endogenously produced fragment of cardiac myosin-binding protein C is pathogenic and can lead to heart failure. *Circ Res* 2013;113:553-61.
24. Gaze DC, Collinson PO. Multiple molecular forms of circulating cardiac troponin: analytical and clinical significance. *Ann Clin Biochem* 2008;45:349-55.
25. Turer AT, Addo TA, Martin JL, Sabatine MS, Lewis GD, Gerszten RE, et al. Myocardial ischemia induced by rapid atrial pacing causes troponin T release detectable by a highly sensitive assay: insights from a coronary sinus sampling study. *J Am Coll Cardiol* 2011;57:2398-405.
26. Selvanayagam JB. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. *Circulation* 2005;111:1027-32.
27. Miner-Williams WM, Stevens BR, Moughan PJ. Are intact peptides absorbed from the healthy gut in the adult human? *Nutr Res Rev* 2014;27:308-29.